Open $4.8900
Day Range 4.3800 - 6.3400
52 Week Range 1.4000 - 6.3400
Market Cap $138.05M
Shares Outstanding 43.03M
Public Float 42.93M
Beta 0.65
Rev. per Employee N/A
P/E Ratio N/A
EPS -$1.8834
Yield N/A
Dividend N/A
Ex-Dividend Date N/A
Short Interest 401.16K 04/15/21
% of Float Shorted 0.93%
Average Volume 1.08M

5 Day	61.56%
1 Month	73.43%
3 Month	68.14%
YTD	96.83%
1 Year	195.24%

Sell
Under
Hold
Over
Buy

Number of Ratings 3 Full Ratings

MarketWatch
Dow Jones

BioLine RX stock price target raised to $10 from $5 at Maxim Group

May. 4, 2021 at 2:09 p.m. ET by Tomi Kilgore

BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment

May. 4, 2021 at 8:56 a.m. ET by Tomi Kilgore

BioLine stock soars on heavy volume after 'compelling' results of cancer treatment trial

Oct. 30, 2020 at 9:11 a.m. ET by Tomi Kilgore

BioLine RX started at outperform with $3 stock price target at Oppenheimer

Aug. 4, 2017 at 8:21 a.m. ET by Tomi Kilgore

Barron's

BiolineRX Shares Could Triple

May. 19, 2017 at 1:03 p.m. ET

Barron's

Four Small Biotechs See Bullish April Stock Buys

May. 3, 2017 at 5:51 a.m. ET by Barron's

BioLine RX stock price target cut to $1 from $4 at Maxim Group

Aug. 12, 2016 at 7:23 a.m. ET by Tomi Kilgore

Darden shares rise after earnings beat

Dec. 16, 2014 at 6:38 p.m. ET by Victor Reklaitis

BioLineRx's stock rallies after collaboration agreement with Novartis Pharma

Dec. 16, 2014 at 7:19 a.m. ET by Tomi Kilgore

BioLineRx's stock soars 17% premarket after collaboration pact with Novartis Pharma

Dec. 16, 2014 at 7:13 a.m. ET by Tomi Kilgore

Monday’s biggest gaining and declining stocks

Sep. 25, 2012 at 6:41 p.m. ET by David B. Wilkerson

Tuesday’s biggest gaining and declining stocks

Sep. 25, 2012 at 5:09 p.m. ET by David B. Wilkerson

Stocks to Watch Wednesday: Jabil Circuit

Sep. 25, 2012 at 4:37 p.m. ET by David B. Wilkerson

Vertex to advance testing of oral HCV drug regimen

Sep. 25, 2012 at 10:34 a.m. ET by Val Brickates Kennedy

BioLine up 16% on schizophrenia patent move

Sep. 24, 2012 at 9:21 a.m. ET by Steve Gelsi

BioLine RX rallies 15% in premarket

Sep. 24, 2012 at 9:10 a.m. ET by Steve Gelsi

BioLine gets U.S. patent for schizophrenia drug

Sep. 24, 2012 at 8:54 a.m. ET by Greg Morcroft

BioLine RX shares jump 36%

Sep. 24, 2012 at 8:52 a.m. ET by Greg Morcroft

Achillion, Idenix move on price target changes

Sep. 19, 2012 at 10:29 a.m. ET by Val Brickates Kennedy

Idenix plunges 30% on HCV drug setback

Aug. 16, 2012 at 12:56 p.m. ET by Val Brickates Kennedy

No Headlines Available

Other News
Press Releases

Analysts Offer Insights on Healthcare Companies: Biolinerx (BLRX) and Verona Pharma (VRNA)

May. 4, 2021 at 1:45 p.m. ET on SmarterAnalyst

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

May. 4, 2021 at 6:59 a.m. ET on InvestorPlace.com

Today’s Biggest Pre-Market Movers: 10 Top Gainers and Losers on Thursday Morning

Apr. 22, 2021 at 7:14 a.m. ET on InvestorPlace.com

Biolinerx (BLRX) Gets a Buy Rating from Maxim Group

Feb. 26, 2021 at 8:28 a.m. ET on SmarterAnalyst

Biolinerx (BLRX) Gets a Buy Rating from Oppenheimer

Feb. 24, 2021 at 5:02 a.m. ET on SmarterAnalyst

Biolinerx (BLRX) Gets a Buy Rating from Oppenheimer

Feb. 24, 2021 at 3:56 a.m. ET on SmarterAnalyst

H.C. Wainwright Remains a Buy on Biolinerx (BLRX)

Feb. 24, 2021 at 2:15 a.m. ET on SmarterAnalyst

These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts

Jan. 28, 2021 at 11:31 a.m. ET on TipRanks.com

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Jan. 20, 2021 at 10:30 a.m. ET on Zacks.com

RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

Jan. 7, 2021 at 9:28 a.m. ET on Zacks.com

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

Dec. 31, 2020 at 9:29 a.m. ET on Zacks.com

Analysts Offer Insights on Healthcare Companies: Biolinerx (BLRX) and Miragen Therapeutics (MGEN)

Dec. 17, 2020 at 11:05 a.m. ET on SmarterAnalyst

Biolinerx (BLRX) Received its Third Buy in a Row

Dec. 16, 2020 at 2:35 p.m. ET on SmarterAnalyst

H.C. Wainwright Keeps Their Buy Rating on Biolinerx (BLRX)

Dec. 16, 2020 at 1:45 p.m. ET on SmarterAnalyst

Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

Dec. 16, 2020 at 10:45 a.m. ET on Zacks.com

Fusion Pharmaceuticals (FUSN) Jumps: Stock Rises 9%

Dec. 1, 2020 at 8:34 a.m. ET on Zacks.com

Oppenheimer Remains a Buy on Biolinerx (BLRX)

Nov. 24, 2020 at 3:07 a.m. ET on SmarterAnalyst

Analysts Are Bullish on Top Healthcare Stocks: Biolinerx (BLRX), Intercept Pharma (ICPT)

Nov. 19, 2020 at 10:45 a.m. ET on SmarterAnalyst

Pacira (PCRX) Gets European Commission Approval for Exparel

Nov. 19, 2020 at 10:08 a.m. ET on Zacks.com

Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EU

Nov. 16, 2020 at 10:06 a.m. ET on Zacks.com

No Headlines Available

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its oncology programs include Motaxafortide (BL-8040), which is therapy platform used in the treatment of pancreatic cancer; and AGI-134 is a immunotherapy treatment used fro multiple solid tumors. The company was founded in April 2003 and is headquartered in Modi'in, Israel.